<i>In vitro</i> experiments demonstrated that the extract of LBT (50 μg/ml) significantly reversed the decline in the survival rate and migration ability of HLECs caused by lipopolysaccharide (LPS; <i>p</i> < 0.01 and <i>p</i> < 0.001), and downregulated the mRNA expression of PRKCB (<i>p</i> < 0.05), and upregulated the mRNA expression of PROX1 (<i>p</i> < 0.05).<h4>Conclusion</h4>This study reveals that LBT may ameliorate LEC dysfunction in lymphedema by targeting PRKCB to disrupt the bidirectional "inflammation-metabolism" vicious cycle. This evidence concerns the gene PRKCB and lymphedema.